GlaxoSmithKline reports positive data from two Phase III trials of eltrombopag in thromboyctopenia

GlaxoSmithKline reported Tuesday at the American Association for the Study of Liver Diseases annual meeting that in two late-stage trials, its experimental drug eltrombopag helped patients with thrombocytopenia achieve "statistically significant" improvement in sustained virological response (SVR).
"The ENABLE trials provide insight into a population that has generally been excluded from clinical trials because they are unable to initiate interferon therapy," remarked Rafael Amado, senior vice president of Oncology Development at GlaxoSmithKline.